Evidence map›Paper›PMID 40908286›Full record

ArticleNature communications2025

Identification of Neuritin 1 as a local metabolic regulator of brown adipose tissue.

Manuela Sánchez-Feutrie, Montserrat Romero, Sónia R Veiga, Núria Borràs-Ferré, Nick Berrow, Martina Ràfols, Noemí Giménez, Andrea Rodgers-Furones, Alba Sabaté-Pérez, Ángela Rodríguez Pérez and 14 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Manuela Sánchez-FeutrieInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain. manuela.sanchez@irbbarcelona.org.
Montserrat RomeroInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.
Sónia R VeigaInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0003-0115-7651
Núria Borràs-FerréInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.
Nick BerrowInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0002-6104-4117
Martina RàfolsInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.
Noemí GiménezInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.
Andrea Rodgers-FuronesInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.
Alba Sabaté-PérezInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.
Ángela Rodríguez PérezInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.ORCID http://orcid.org/0009-0006-2939-1377
Luis Rodrigo CataldoInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0003-1225-414X
Hans BurghardtInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.
David SebastiánInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.
Natàlia PlanaInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.
Vanessa HernándezInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.
Laura Isabel AlcaideInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.
Óscar ReinaInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.
Maria J MonteExperimental Hepatology and Drug Targeting (HEVEPHARM), Universidad de Salamanca; Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), ISCIII, Madrid, Spain.ORCID http://orcid.org/0000-0003-1844-7428
José Juan G MarinExperimental Hepatology and Drug Targeting (HEVEPHARM), Universidad de Salamanca; Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), ISCIII, Madrid, Spain.ORCID http://orcid.org/0000-0003-1186-6849
Manuel PalacínInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain.ORCID http://orcid.org/0000-0002-8670-293X
Remy BurcelinUMR 1297 INSERM, Team INCOMM Rangueil Hospital, Toulouse, 31400, France.ORCID http://orcid.org/0000-0002-7942-8346
Per AntonsonDepartment of Medicine Huddinge, Karolinska Institutet, Neo, SE-141 83, Huddinge, Sweden.ORCID http://orcid.org/0000-0001-9335-9941
Jan-Ake GustafssonDepartment of Medicine Huddinge, Karolinska Institutet, Neo, SE-141 83, Huddinge, Sweden.
Antonio ZorzanoInstitute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10, 08028, Barcelona, Spain. antonio.zorzano@irbbarcelona.org.ORCID http://orcid.org/0000-0002-1638-0306

Funding

"la Caixa" Foundation (Caixa Foundation) 2022-1256
6 · The paper itself

Abstract

Brown adipose tissue (BAT) plays a key role in metabolic homeostasis through its thermogenic effects and the secretion of regulatory molecules. Here we report that RAP250 haploinsufficiency stimulates BAT in mice, thus contributing to a decrease in fat accumulation. Local in vivo AAV-mediated RAP250 silencing in BAT reduces body weight and fat mass and enhances glucose oxidation, thereby indicating that RAP250 participates in the regulation of BAT metabolic activity. Analysis of the mechanisms led to the finding that Neuritin 1 is produced and released by brown adipocytes, it plays a key metabolic role, and it participates in the enhanced BAT metabolic activity under RAP250 deficiency. Forced overexpression of Neuritin 1 in UCP1-expressing cells markedly decreases fat mass and body weight gain in mice and induces the expression of thermogenic genes in BAT. Neuritin 1-deficient brown adipocytes also shows a reduced β-adrenergic response. We demonstrate a metabolic role of BAT-derived Neuritin 1 acting through an autocrine/paracrine mechanism. Based on our results, Neuritin-1 emerges as a potential target for the treatment of metabolic disorders.

Indexed as

Adipose Tissue, BrownAdipocytes, BrownAnimalsGlucoseHumansMaleMiceMice, Inbred C57BLMice, KnockoutThermogenesisUncoupling Protein 1GlucoseUcp1 protein, mouseUncoupling Protein 1

Identifiers

PMID40908286
PMCPMC12411623

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.